Erythroleukemia and other hematologic complications of intensive therapy in long‐term survivors of small cell lung cancer

Edward C. Bradley, Geraldine P. Schechter, Mary J. Matthews, Jacqueline Whang‐Peng, Martin H. Cohen, Paul A. Bunn, Daniel C. Ihde, John D. Minna

研究成果: 雜誌貢獻文章

32 引文 斯高帕斯(Scopus)

摘要

Eight patients with small cell bronchogenic carcinoma treated with intensive combination chemotherapy, with and without radiotherapy, have been followed for a minimum of two and a half years without relapse. One patient, after a prodrome of macrocytic sideroblastic anemia, leukopenia, and thrombocytopenia, experienced erythroleukemia 34 months after starting chemotherapy, and cytogenetic studies revealed extensive chromosomal abnormalities. Another patient had persistent macrocytic anemia and pancytopenia two years after cessation of therapy. The remaining six patients have normal peripheral blood smears and cell counts. A significant incidence of preleukemic syndromes and acute leukemia appearing as late complications in intensively treated small cell lung cancer patients requires confirmation in larger series of long‐term survivors. Prospective determination of marrow karyotype abnormalities may help to identify patients at greatest risk for developing secondary leukemia.
原文英語
頁(從 - 到)221-223
頁數3
期刊Cancer
49
發行號2
DOIs
出版狀態已發佈 - 一月 1 1982
對外發佈Yes

    指紋

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

引用此